Cvrx Inc (CVRX)

$9.27 +0.36 (4.04%)
Market Cap 233.53M
Revenue (ttm) 51.29M
Net Income (ttm) -59.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -116.92%
Debt to Equity Ratio 1.03
Volume 256,700
Avg Vol 212,696
Day's Range N/A - N/A
Shares Out 26.21M
Stochastic %K 39%
Beta 1.28
Analysts Strong Sell
Price Target $11.50

Company Profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was...

Industry: Medical Devices
Sector: Healthcare
Phone: 763 416 2840
Fax: 763 416 2841
Address:
9201 West Broadway Avenue, Suite 650, Minneapolis, United States
MedDevice
MedDevice Nov. 14 at 3:59 PM
$CVRX how can this company undertake the largest medical device trial in history? can they actually conduct a 2,000 patient trial in an area that has known to be a dead end for M&M benefit? This will compete with many other trials from more established companies that have made recent investment to these space.
0 · Reply
newfguy
newfguy Nov. 13 at 5:02 PM
$CVRX this board's biggest cheerleader has gone silent
1 · Reply
MedDevice
MedDevice Nov. 7 at 2:34 PM
$CVRX just to reiterate, using a $28K asp, revenue per center remains flat. Using the recently reported $29K asp, Q3 2025 was again under 2 units per quarter.
0 · Reply
Twister8
Twister8 Nov. 7 at 5:22 AM
$CVRX dead $$$$
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 7:58 PM
Canaccord Genuity has updated their rating for CVRx ( $CVRX ) to Buy with a price target of 11.
0 · Reply
erevnon
erevnon Nov. 6 at 3:53 PM
Cantor Fitzgerald maintains CVRx $CVRX at Overweight and raises the price target from $11 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Nov. 6 at 3:23 PM
$CVRX Buy Canaccord Genuity raises target price to $11 from $9
0 · Reply
Twister8
Twister8 Nov. 6 at 3:01 PM
$CVRX where is the Donald?
0 · Reply
MedDevice
MedDevice Nov. 6 at 2:48 PM
$CVRX cash position relative to future growth and costs warrant the need for a cash raise.
0 · Reply
MedDevice
MedDevice Nov. 6 at 2:43 PM
$CVRX mid teens projection at a minimum is a 16% reduction in 2026 growth from the 18% previous. Costs going up. Revenue per center not growing. Zero confirmation of sales force “enhancements” being effective in the short term. Wavering on the tier 1 & 2 strategy. Continued decrease in marketing expenses (DTC?). Study not finalized until 2026 equates to first enrollments in back half of 2026 minimum. Cat 1 code removes only the automatic denial but still requires PA based on clinical evidence, which was only a failed endpoint from BeAT. All the new site launch PR is not resulting in same store sales growth but supporting revenue that can’t / isn’t exceeding 2 revenue units per quarter. Very very
0 · Reply
Latest News on CVRX
CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 10:51 PM EST - 9 days ago

CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

Oct 22, 2025, 4:30 PM EDT - 24 days ago

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 7:27 PM EDT - 3 months ago

CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

CVRx Reports Second Quarter 2025 Financial and Operating Results

Aug 4, 2025, 4:05 PM EDT - 3 months ago

CVRx Reports Second Quarter 2025 Financial and Operating Results

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 8:30 AM EDT - 3 months ago

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

CVRx Announces Positive News on Outpatient Payment for Barostim

Jul 16, 2025, 7:30 AM EDT - 4 months ago

CVRx Announces Positive News on Outpatient Payment for Barostim

CVRx: Sell-Off Ignores Its True Potential

Jul 2, 2025, 4:02 AM EDT - 4 months ago

CVRx: Sell-Off Ignores Its True Potential

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

May 28, 2025, 4:30 PM EDT - 6 months ago

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript

May 10, 2025, 3:51 PM EDT - 6 months ago

CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

Apr 24, 2025, 4:30 PM EDT - 7 months ago

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

CVRx Inc: Overreaction Creates Buying Opportunity

Apr 9, 2025, 8:45 AM EDT - 7 months ago

CVRx Inc: Overreaction Creates Buying Opportunity

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Apr 8, 2025, 8:35 AM EDT - 7 months ago

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

GBX RPM

CVRx Reports Preliminary First Quarter 2025 Financial Results

Apr 7, 2025, 4:05 PM EDT - 7 months ago

CVRx Reports Preliminary First Quarter 2025 Financial Results

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

Feb 12, 2025, 2:45 PM EST - 9 months ago

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript

Feb 4, 2025, 11:00 PM EST - 10 months ago

CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 4, 2025, 4:05 PM EST - 10 months ago

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

Jan 21, 2025, 4:30 PM EST - 10 months ago

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 4:30 PM EST - 11 months ago

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

CVRx: Impressive Top-Line Growth Seems Priced In

Nov 6, 2024, 9:04 PM EST - 1 year ago

CVRx: Impressive Top-Line Growth Seems Priced In

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 10:38 PM EDT - 1 year ago

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript

CVRx announces new CPT® Category I codes for Barostim

Oct 18, 2024, 2:08 PM EDT - 1 year ago

CVRx announces new CPT® Category I codes for Barostim

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

Oct 15, 2024, 4:30 PM EDT - 1 year ago

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

CVRx Announces Appointment of Two New Board Members

Sep 3, 2024, 8:30 AM EDT - 1 year ago

CVRx Announces Appointment of Two New Board Members

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 19, 2024, 4:00 PM EDT - 1 year ago

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join

Aug 19, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join

The Schall Law Firm Is Seeking CVRx Inc Shareholders To Join Fraud Investigation

Aug 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Seeking CVRx Inc Shareholders To Join Fraud Investigation

CVRx Inc Shareholders Can Join Fraud Investigation With The Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Shareholders Can Join Fraud Investigation With The Schall Law Firm

CVRx Inc Investors Encouraged To Participate In Fraud Inquiry With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Investors Encouraged To Participate In Fraud Inquiry With The Schall Law Firm

CVRx Inc Shareholders Urged To Participate In Fraud Inquiry With The Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Shareholders Urged To Participate In Fraud Inquiry With The Schall Law Firm

CVRx Inc Shareholders Invited To Join Fraud Inquiry With The Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

CVRx Inc Shareholders Invited To Join Fraud Inquiry With The Schall Law Firm

CVRx Inc Investors May Participate In Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 12:30 AM EDT - 1 year ago

CVRx Inc Investors May Participate In Fraud Investigation With The Schall Law Firm

CVRx Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Aug 13, 2024, 2:00 AM EDT - 1 year ago

CVRx Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

CVRx Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 8:30 PM EDT - 1 year ago

CVRx Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

CVRx Inc Investors Can Join Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

CVRx Inc Investors Can Join Fraud Investigation With The Schall Law Firm

CVRx Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 4:15 PM EDT - 1 year ago

CVRx Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm

MedDevice
MedDevice Nov. 14 at 3:59 PM
$CVRX how can this company undertake the largest medical device trial in history? can they actually conduct a 2,000 patient trial in an area that has known to be a dead end for M&M benefit? This will compete with many other trials from more established companies that have made recent investment to these space.
0 · Reply
newfguy
newfguy Nov. 13 at 5:02 PM
$CVRX this board's biggest cheerleader has gone silent
1 · Reply
MedDevice
MedDevice Nov. 7 at 2:34 PM
$CVRX just to reiterate, using a $28K asp, revenue per center remains flat. Using the recently reported $29K asp, Q3 2025 was again under 2 units per quarter.
0 · Reply
Twister8
Twister8 Nov. 7 at 5:22 AM
$CVRX dead $$$$
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 7:58 PM
Canaccord Genuity has updated their rating for CVRx ( $CVRX ) to Buy with a price target of 11.
0 · Reply
erevnon
erevnon Nov. 6 at 3:53 PM
Cantor Fitzgerald maintains CVRx $CVRX at Overweight and raises the price target from $11 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Nov. 6 at 3:23 PM
$CVRX Buy Canaccord Genuity raises target price to $11 from $9
0 · Reply
Twister8
Twister8 Nov. 6 at 3:01 PM
$CVRX where is the Donald?
0 · Reply
MedDevice
MedDevice Nov. 6 at 2:48 PM
$CVRX cash position relative to future growth and costs warrant the need for a cash raise.
0 · Reply
MedDevice
MedDevice Nov. 6 at 2:43 PM
$CVRX mid teens projection at a minimum is a 16% reduction in 2026 growth from the 18% previous. Costs going up. Revenue per center not growing. Zero confirmation of sales force “enhancements” being effective in the short term. Wavering on the tier 1 & 2 strategy. Continued decrease in marketing expenses (DTC?). Study not finalized until 2026 equates to first enrollments in back half of 2026 minimum. Cat 1 code removes only the automatic denial but still requires PA based on clinical evidence, which was only a failed endpoint from BeAT. All the new site launch PR is not resulting in same store sales growth but supporting revenue that can’t / isn’t exceeding 2 revenue units per quarter. Very very
0 · Reply
newfguy
newfguy Nov. 6 at 2:40 PM
$CVRX slow grower with no profits. exited position
0 · Reply
Twister8
Twister8 Nov. 6 at 2:37 PM
$CVRX looking sub 9
0 · Reply
Twister8
Twister8 Nov. 6 at 2:36 PM
$CVRX pump and dump
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 2:30 PM
Cantor Fitzgerald has adjusted their stance on CVRx ( $CVRX ), setting the rating to Overweight with a target price of 11 → 13.
0 · Reply
healthcareguru
healthcareguru Nov. 6 at 2:11 PM
$CVRX on top of a blah qtr & guide, they just filed shelf for $150MN offering… 👎
0 · Reply
Twister8
Twister8 Nov. 6 at 1:33 PM
$CVRX once bitten twice shy as mgmt goes conservative.
0 · Reply
Twister8
Twister8 Nov. 6 at 4:04 AM
$CVRX Final Takeaway CVRx management highlights solid revenue growth, significant progress in sales force productivity, and substantial advances in reimbursement that are expected to reduce barriers and support future adoption of Barostim therapy. The company targets mid-teens growth in 2026 as recent investments and evolving market access set the stage for acceleration, while maintaining a strong cash position and cautious optimism as execution on these priorities continues.
1 · Reply
Twister8
Twister8 Nov. 6 at 3:53 AM
$CVRX Hykes noted, "We added 10 net new centers this quarter and are seeing traction with this approach. Our top accounts are demonstrating the deepening adoption that is the hallmark of an established Barostim program. More than 20% of our active implanting centers achieved 3 or more implants in Q3, and our highest performing sites are now implanting more than 10 patients per quarter."
1 · Reply
Twister8
Twister8 Nov. 6 at 3:23 AM
$CVRX Hykes over promised and under delivered, sell the horseshit.
2 · Reply
healthcareguru
healthcareguru Nov. 5 at 10:35 PM
$CVRX this was not a satisfying print after having run up 50% in the past 3mos. Barely beat sales and guide inching nowhere. Let down. Buyer <$8.
1 · Reply
davidbo
davidbo Nov. 5 at 10:26 PM
$CVRX solid cc,conservative guide,3rd party payers on board, appears they have there act together, insiders buying big or holding for better performance. Should move up nicely.
0 · Reply
MedDevice
MedDevice Nov. 5 at 10:07 PM
$CVRX last question referenced some sites doing 10 or more per quarter? Where is that data coming from in the report? That’s a key piece of information.
1 · Reply